Pilot RCT: FQHC Intervention for Uptake of CGM in Low-Income Adults With T1D
Launched by UNIVERSITY OF CONNECTICUT · Jun 27, 2024
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying how to help Hispanic adults with type 1 diabetes (T1D) use continuous glucose monitoring (CGM) devices more effectively. CGM devices are helpful tools that can track blood sugar levels continuously, which can prevent serious health issues like hypoglycemia (low blood sugar) and diabetes ketoacidosis (a dangerous condition caused by high blood sugar). Unfortunately, many Hispanic adults with T1D have not been using these devices, even though they could greatly benefit from them. The trial aims to test a new program that provides support and training to make it easier for these individuals to start using CGM.
To be eligible for the study, participants must be Hispanic adults over 24 years old, have a confirmed diagnosis of type 1 diabetes, and receive their diabetes care from a federally qualified health center (FQHC). They should also be comfortable speaking English or Spanish and willing to wear a CGM sensor. Participants will attend four intervention sessions with an adult family member or friend who can help support them during the process. This study is currently recruiting, and it is a great opportunity for those who might struggle with using CGM to get the guidance they need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Low-income status
- • Documented diagnosis of T1D
- • 18 years of age or older
- • Federally Qualified Health Center (FQHC) primary care provider
- • English or Spanish-speaking And at intervention sites
- • Willingness to wear a CGM sensor
- • Adult family member or friend, who will give consent to participate in the study and co-attend the 4-week intervention sessions
- • Reported difficulty in using CGM if current or past use of CGM
- Exclusion Criteria:
- • Pregnancy or planning to become pregnant
- • Lactation
- • Serious illness that may prevent study participation (e.g., severe depression)
- • Less than 6 months life expectancy
- • Alcohol abuse or dependence
- • Uncorrected hearing or vision impairment
About University Of Connecticut
The University of Connecticut (UConn) is a leading academic institution committed to advancing health and science through innovative research and education. As a clinical trial sponsor, UConn leverages its extensive resources, including renowned faculty and state-of-the-art facilities, to conduct rigorous studies that contribute to medical knowledge and improve patient care. The university fosters a collaborative environment, engaging multidisciplinary teams to explore novel therapies and interventions across various health-related fields. UConn's dedication to ethical practices and compliance ensures the integrity and reliability of its clinical research, ultimately aiming to enhance health outcomes and address critical challenges in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Middletown, Connecticut, United States
Vero Beach, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported